Glycogen storage disease type III: Difference between revisions
No edit summary |
Irfan Dotani (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}}; {{AE}} | |||
{{SK}} Glycogen storage disease type III; Cori's disease; Forbes disease; limit dextrinosis; glycogenosis type 3; amylo-1, 6-glucosidase deficiency; debrancher enzyme deficiency; glycogen debranching enzyme deficiency | |||
{{Infobox_Disease | {{Infobox_Disease | ||
| Name = Glycogen storage disease type III | | Name = Glycogen storage disease type III | ||
Line 12: | Line 17: | ||
| MeshID = D006010 | | MeshID = D006010 | ||
}} | }} | ||
==Overview== | ==Overview== | ||
Line 23: | Line 24: | ||
GSD III is inherited in an [[autosomal recessive]] manner and occurs in about 1 of every 100,000 live births. | GSD III is inherited in an [[autosomal recessive]] manner and occurs in about 1 of every 100,000 live births. | ||
==Historical Perspective== | |||
==Classification== | |||
==Pathophysiology== | |||
==Causes== | |||
==Differentiating {{PAGENAME}} from Other Diseases== | |||
==Epidemiology and Demographics== | |||
==Risk Factors== | |||
==Screening== | |||
==Natural History, Complications, and Prognosis== | |||
==Diagnosis== | ==Diagnosis== | ||
Line 35: | Line 54: | ||
The liver pathology typically regresses as patients enter [[adolescence]], and few patients develop [[cirrhosis]] during adulthood. | The liver pathology typically regresses as patients enter [[adolescence]], and few patients develop [[cirrhosis]] during adulthood. | ||
== | ===Diagnostic Criteria=== | ||
===History and Symptoms=== | |||
===Physical Examination=== | |||
===Laboratory Findings=== | |||
===Imaging Findings=== | |||
===Other Diagnostic Studies=== | |||
==Treatment== | |||
Treatment may involve a high [[protein]] diet, in order to facilitate [[gluconeogenesis]]. | Treatment may involve a high [[protein]] diet, in order to facilitate [[gluconeogenesis]]. | ||
===Medical Therapy=== | |||
===Surgery=== | |||
===Prevention=== | |||
==Related chapters== | ==Related chapters== | ||
*[[Glycogen storage disease type I]] | *[[Glycogen storage disease type I]] | ||
*[[Glycogen storage disease type II]] | *[[Glycogen storage disease type II]] | ||
*[[Glycogen storage disease type IV]] | *[[Glycogen storage disease type IV]] | ||
==References== | |||
{{reflist|2}} | |||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[de:Cori-Krankheit]] | [[de:Cori-Krankheit]] |
Revision as of 15:43, 22 July 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Synonyms and keywords: Glycogen storage disease type III; Cori's disease; Forbes disease; limit dextrinosis; glycogenosis type 3; amylo-1, 6-glucosidase deficiency; debrancher enzyme deficiency; glycogen debranching enzyme deficiency
Glycogen storage disease type III | |
ICD-10 | E74.0 |
---|---|
ICD-9 | 271.0 |
OMIM | 232400 |
DiseasesDB | 5302 |
MeSH | D006010 |
Overview
Glycogen storage disease type III is a genetic disorder, an inborn error of metabolism characterized by a deficiency in glycogen debranching enzymes. It is also known as Cori's disease in honor of the 1947 Nobel laureates Carl Cori and Gerty Cori. Other names include Forbes disease in honor of a clinician who further described the features of the disorder, or limit dextrinosis.[1]
Glycogen is a molecule the body uses to store carbohydrate energy. Symptoms of GSD-III are caused by a deficiency of the enzyme amylo-1,6 glucosidase, or debrancher enzyme. This causes excess amounts of an abnormal glycogen to be deposited in the liver, muscles and, in some cases, the heart.
GSD III is inherited in an autosomal recessive manner and occurs in about 1 of every 100,000 live births.
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glycogen storage disease type III from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Clinical manifestations are divided into four classes:
- GSD IIIa, which clinically includes muscle and liver involvement [2]
- GSD IIIb, which clinically has liver involvement but no muscle involvement
- GSD IIIc and GSD IIId, which are rarer phenotypes with altered penetrance
The disease typically presents during infancy with hypoglycemia and failure to thrive. Clinical examination usually reveals hepatomegaly. Muscular disease, including hypotonia and cardiomyopathy usually occurs later.
The liver pathology typically regresses as patients enter adolescence, and few patients develop cirrhosis during adulthood.
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Treatment may involve a high protein diet, in order to facilitate gluconeogenesis.
Medical Therapy
Surgery
Prevention
Related chapters
References
- ↑ http://www.emedicine.com/ped/topic479.htm.
- ↑ Lucchiari S et al., Clinical and genetic variability of glycogen storage disease type IIIa: seven novel AGL gene mutations in the Mediterranean area. Am J Med Genet 2002 May 1;109(3):183-90.